GT Biopharma Announces Interim GTB-3550 Trike™ Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference

57% of patients experienced significant reduction in AML/MDS cancer cell burden Up…

Dr. Jeffrey S. Miller to Present on Progress of GTB-3550 TriKE™ Phase I Trial Accompanying GT Biopharma’s Company Presentation at Raymond James Human Health Innovation Conference

BEVERLY HILLS, Calif., June 21, 2021 /PRNewswire/ — GT Biopharma, Inc. (“GT…

GT Biopharma to Present at Raymond James Human Health Innovation Conference

BEVERLY HILLS, Calif., June 16, 2021 /PRNewswire/ — GT Biopharma, Inc. (“GT…

GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates

BEVERLY HILLS, Calif., May 12, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

Beyond Medical Subsidiary Micron Technologies Achieves “Amazon’s Choice” Designation and Begins to Accept Bitcoin Payments for its Made in Canada Face Masks

VANCOUVER, BC, April 27, 2021 /CNW/ – Beyond Medical Technologies Inc. (“Beyond…

GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial

BEVERLY HILLS, Calif., April 8, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

GT Biopharma’s TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021

Outlines the Clinical Power of Immune Engagement with IL-15 Containing TriKEs BEVERLY…

Havn Life CEO to Present at Zooming with LD, a Leading Platform for Microcap Companies

CEO Tim Moore will appear on Tuesday, March 24th at 8:00 AM…